We read with great interest the report by Ilowite et al, summarizing the results of a trial investigating the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis (JIA) [@b1]. We believe a statement made in the article is incorrect and needs clarification.

In the Discussion section, the authors stated the following about the circulating half-life of rilonacept: "Rilonacept could offer an alternative \[context: to canakinumab\], with its circulating half-life of 8.6 days, in contrast to the long biologic activity of canakinumab (236 days), which could be a disadvantage in the setting of an SAE \[context: serious adverse event\]."

This statement, however, does not seem fully consistent with the published literature. In adults with cryopyrin-associated periodic syndromes (CAPS), the mean terminal half-life of canakinumab was demonstrated to be 26 days, with the terminal half-life in pediatric CAPS patients found to be similar to that in adults [@b2]. Pharmacokinetic properties of canakinumab are similar in the CAPS and systemic JIA pediatric populations [@b2]. From a pharmacokinetic standpoint, based on the known 26-day half-life of canakinumab, 5--6 half-lives is 130--156 days, a range that encompasses another relevant efficacy end point, the median time to worsening in the adapted American College of Rheumatology Pediatric criteria level in the withdrawal arm (placebo) of the phase III study from which the 236-day data point was derived [@b3]--[@b6].

While extensive postmarketing and phase IV surveillance data are not yet available, there has been no indication in the available safety data that the 26-day half-life of canakinumab is problematic in the management of serious adverse events.
